More Children Are Being Diagnosed with Diabetes after Pandemic

February 28, 2022 09:35:00

Type 1 diabetes is also referred to as insulin-dependent diabetes or juvenile diabetes. It’s a chronic condition in which the pancreas produces no insulin or little insulin. Insulin is a hormone required in the body that allows glucose (sugar) to enter cells in order to produce energy.

Since the coronavirus pandemic began, doctors have observed a significant increase in diagnoses for type 1 diabetes, particularly in children. Various factors may contribute to the development of type 1 diabetes, the most common being genetics and exposure to some viruses, as well as other environmental factors. While this chronic condition usually appears during childhood or adolescence, it can also develop in adults.

Dr. Roberto Izquierdo, a pediatric endocrinologist in central New York, revealed that before the pandemic, he saw nearly 100 patients with both type 1 and 2 diabetes; type 1 was the most common. However, this number shot up to almost 150 in 2021.

Unlike type 1 diabetes, type 2 diabetes is a chronic condition that occurs when an individual’s body doesn’t use and regulate glucose in a normal way. It results from too much sugar circulating in an individual’s bloodstream. Insulin helps lower the amount of sugar in an individual’s bloodstream.

Studies conducted recently support these claims, with physicians in San Diego recording 57% increases in cases of type 1 diabetes in young people. Symptoms of type 1 diabetes include frequent urination, increased thirst, extreme hunger, bedwetting in children who don’t normally wet the bed, mood changes such as irritability, unintended weight loss, blurred vision, weakness and fatigue.

A recently released morbidity and mortality report by the CDC highlighted the increased risk for diabetes among children more than a month after a coronavirus infection.

Izquierdo stated that the number-one thing to do was to get children into treatment as soon as possible in order to avoid a life-threatening diabetes complication known as ketoacidosis. He also explained that different types of insulin exist that allow doctors to adjust an individual’s blood sugar, noting that continued glucose monitoring through the use of technologies such as the devices manufactured by Nemaura Medical Inc. (NASDAQ: NMRD) was also a way to keep children from having to check their blood sugar regularly. In addition to this, the presence of insulin pumps also helped as they delivered insulin constantly, which helped improve the quality of life for kids.

It should be noted that type 1 diabetes still has no cure. Treatment focuses on managing levels of blood sugar with insulin, lifestyle and diet to hinder complications from occurring.

NOTE TO INVESTORS: The latest news and updates relating to Nemaura Medical Inc. (NASDAQ: NMRD) are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.